Abogen licenses its mRNA-encoded T-cell engager to Novartis, expanding the latter's immuno-oncology pipeline
Executive summary: Abogen announced a licensing and option agreement with Novartis for its mRNA‑encoded CD19xCD3 T‑cell engager (ABO2203) and for additional RNA programs using Abogen’s platform. The agreement expands Novartis’ immuno‑oncology pipeline with a novel mRNA‑based therapeutic and provides Abogen with financing, milestones and validation of its RNA technology.
Who is involved: Abogen Biosciences and Novartis.
Likely next: Novartis may decide to exercise its options for further RNA programs; Abogen will likely advance ABO2203 toward IND‑enabling studies.
Abogen Biosciences announced a worldwide license to Novartis for its mRNA‑encoded CD19xCD3 T‑cell engager (ABO2203) and granted Novartis exclusive options to license additional RNA programs from Abogen’s proprietary platform. The deal gives Novartis a new immuno‑oncology candidate that could complement its existing cell‑therapy and biologics portfolio, while Abogen receives an upfront payment, potential milestones and royalties. By tying its RNA technology to a major pharma partner, Abogen validates its platform and gains resources to advance its pipeline toward clinical testing.
What's next — scenarios
Base: one option exercised, IND‑enabling work progresses (50%)
Novartis gains a second mRNA‑based asset while Abogen advances its lead candidate toward clinical trials.
- Novartis announces exercise of an option under the agreement within the next 12 months
- Abogen reports completion of IND‑enabling studies for ABO2203 by Q4 2026
Upside: multiple options exercised, Phase I starts (30%)
Expanded collaboration accelerates Novartis’ immuno‑oncology pipeline and provides Abogen with milestones and royalty streams.
- Novartis exercises options for at least two additional RNA programs by mid‑2027
- Abogen files an IND for ABO2203 with the FDA or EMA by end 2027
Downside: no options exercised, development stalls (20%)
Abogen relies solely on the upfront license fee, while Novartis focuses on other pipeline assets.
- Novartis publicly states it will not exercise any options under the agreement by end 2027
- Abogen reports no further development updates on ABO2203 for six consecutive months
What to watch
- Any announcement from Novartis regarding exercise of options under the Abogen agreement
- Updates from Abogen on IND‑enabling progress for ABO2203
- Public presentations or preclinical data releases for ABO2203 at scientific conferences
Timeline
- — Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs (PR Newswire)
- — CAS announces collaboration with Novartis to advance AI-ready reaction informatics (PR Newswire)
- — BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset (PR Newswire)
Analysis — what this means
Sectors affected
- mRNA‑based T‑cell engager therapeutics
- immuno‑oncology biotechnology
Key entities
Sources
- Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs — PR Newswire
- CAS announces collaboration with Novartis to advance AI-ready reaction informatics — PR Newswire
- BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset — PR Newswire
Related cases
- Abogen’s mRNA T‑cell engager deal with Novartis expands immunotherapy pipeline and validates its RNA platform
- BoomRay secures exclusive global license with Novartis for a novel radioligand therapy, boosting Novartis' oncology pipeline
- Novartis trial failure triggers sector-wide selloff in biopharma stocks
- Novartis reports positive trial results for a new multiple sclerosis therapy with reduced liver toxicity
- Rznomics partners with Lilly Gateway Labs in San Diego to accelerate its RNA therapeutic pipeline using Lilly’s manufacturing and development infrastructure
- Henlius and Sandoz partner to co‑develop up to ten biosimilar mAb and ADC assets, aiming to accelerate global market access and revenue generation